Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon Jun 20, 2023 6:12pm
144 Views
Post# 35506172

Press Release

Press ReleaseBioasis is announcing that it has pretty much given up. You can find the press release here.

Chiesi has cancelled its agreement with Bioasis. They either see no opportunity with xB3 or they don't want to deal with Bioasis. A term sheet has been signed that may shift the EGF assets back to some Cresence people.

A reason for the failure may be that there is a real or perceived problem with xB3, despite being reassured by every CEO that there are no problems with xB3. 

Other possibilities include the loss of xB3 to the Lind Group. They, in turn, could sell it to a shark who is lying there waiting for it. If Lind does get it, we may never know where xB3 ends up or whether follows it to its new owner.

Imagine, a market waiting for the successful transport of therapeutics across the BBB, a market that is worth billions per year, and Bioasis managements couldn't make a go of it.

We may never know the truth, but we can and will remain very suspicious about how it all went down.

Time to move on. For me, it's Boomskid, almost immediately, and I am pursuing other writing opportuities.

I invite all of you to remain in touch, however and whenever you see fit. 

Sad day...

jd
<< Previous
Bullboard Posts
Next >>